TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9310802
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration (SQA) of inhaled nitric oxide (NO) at 1, 3, and 6 ppm
Study: 9310802
Drug: Continuous administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration (CTA) of inhaled nitric oxide (NO) at 1, 3, and 6 ppm
Study: 8379713
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of autologous platelet-rich plasma (PRP)
Study: 8379713
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of autologous whole blood harvested immediately before cardiopulmonary bypass
Study: 2876576
Drug: ICI-118.551 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI-118.551 (50 mg X 3)
Study: 2876576
Drug: dl-propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl-propranolol (80 mg X 3)
Study: 30460369
Drug: Narrowband ultraviolet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrowband ultraviolet B phototherapy and topical corticosteroid
Study: 30460369
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid only
Study: 29158663
Drug: DA‐2802 (319
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA‐2802 (319 mg)
Study: 29158663
Drug: TDF (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF (300 mg)
Study: 19406293
Drug: Additional ward
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional ward treatment
Study: 16500346
Drug: Fallopian tube
Normalized name: SUS SCROFA FALLOPIAN TUBE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fallopian tube sperm perfusion (FSP) with 4 mL of inseminate
Study: 16500346
Drug: Intrauterine tuboperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine tuboperitoneal insemination (IUTPI) with 10 mL of inseminate
Study: 15625998
Drug: Cincinnati Prehospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cincinnati Prehospital Stroke Scale (CPSS) administered by laypersons over the telephone
Study: 11583725
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg fluvastatin twice daily
Study: 8040674
Drug: Ifosfamide (IFOS)
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide (IFOS) 2 g/m2/d for 4 days IV plus mesna
Study: 8040674
Drug: Carboplatin (CARB)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (CARB) 560 mg/m2 IV over 1 hour
Study: 8040674
Drug: Iproplatin (CHIP)
Normalized name: Aroplatin
DrugBank: Aroplatin (DB17319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iproplatin (CHIP) 325 mg/m2 IV over 2 hours
Study: 8040674
Drug: Epirubicin (EPIR)
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin (EPIR) 90 mg/m2 IV push
Study: 8040674
Drug: CECA (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CECA (cisplatin 90 mg/m2 IV on day 1, etoposide 200 mg/m2 IV on day 3, cyclophosphamide 150 mg/m2/d orally on days 7 to 13, doxorubicin 35 mg/m2 IV on day 14)
Study: 8040674
Drug: HDP/VP/CA (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDP/VP/CA (cisplatin 40 mg/m2 IV on days 1 to 5 and etoposide 200 mg/m2 IV on days 2 to 4 alternating with cyclophosphamide 150 mg/m2/d orally on days 1 to 7 and doxorubicin 35 mg/m2 IV on day 8)
Study: 25989985
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection with physiotherapy
Study: 25989985
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection with physiotherapy
Study: 19234844
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg famotidine in 10 ml saline
Study: 10021958
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml saline
Study: 10770452
Drug: Sertraline 150
Normalized name: sertraline 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 150 mg/day
Study: 10770452
Drug: Alprazolam 1
Normalized name: alprazolam 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 1 mg orally
Study: 6832203
Drug: Paracetamol 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1000 mg administered preoperatively
Study: 6832203
Drug: Paracetamol 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1000 mg administered postoperatively
Study: 31407353
Drug: Melatonin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (1 mg per day for 1 month)
Study: 31407353
Drug: Placebo (NSPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NSPT and placebo capsules for 1 month)
Study: 24964358
Drug: Ritonavir-boosted protease
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted protease inhibitors (PI/r)
Study: 23591103
Drug: Onabotulinumtoxin-A injections
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Onabotulinumtoxin-A injections
Study: 6369348
Drug: Combined medication
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined medication of 150 mg Chlorimipramine and 9 mg p.d. Haloperidol (given over six days)
Study: 2959232
Drug: Ramipril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (10 mg p.o.)
Study: 23237817
Drug: Modified tumescent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified tumescent solution
Study: 20544159
Drug: Functional splint
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional splint used during activities of daily living for 180 days
Study: 20544159
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group used the splint only during evaluations for the first 90 days and during activities of daily living for the following 90 days
Study: 8899256
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg depot‐medroxyprogesterone acetate (DMPA), intramuscularly on days 42 + 1 and 126 + 1 postpartum
Study: 6418690
Drug: 1% sodium
Normalized name: Dextrose 5% and 0.11% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% sodium cromoglycate (SC) solution t.i.d. by means of a home nebulizer
Study: 6418690
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml placebo (water) nebulization
Study: 9455696
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (30 mg per day for 1 month)
Study: 3280304
Drug: Increasing the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing the dose until the level reached and stayed at the therapeutic range (study arm B)
Study: 31115626
Drug: Composite criteria
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Composite criteria using tumor size < 6.0 cm, tumor number < 8, alpha-fetoprotein < 465 ng/mL, TBRmax < 2.8
Study: 19440013
Drug: Eutectic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eutectic mixture of local anesthetics cream (EMLA)
Study: 17848798
Drug: Phantasy Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phantasy Therapy
Study: 9010894
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of one active treatment and placebo
Study: 23982855
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg lidocaine and 100 % O(2) (group L)
Study: 23982855
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg lidocaine and a mixture of 67 % N(2)O/O(2) (group LN)
Study: 21761394
Drug: Caffeine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (150 mg) + Taurine (2 g)
Study: 14747687
Drug: 300 g
Normalized name: Zantac 300 GELdose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 g of fruits and vegetables
Study: 14578137
Drug: 600 g
Normalized name: PETROLATUM 600 g in 1000 g TOPICAL OINTMENT [EltaMD Laser Balm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 g of fruits and vegetables
Study: 8529054
Drug: levodopa (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: levodopa (200 mg) + benserazide (50 mg)
Study: 27120292
Drug: (-)-OSU6162 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (-)-OSU6162 at a dose of 15 mg twice a day
Study: 22035984
Drug: MPS silane
Normalized name: silane
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPS silane (ESPE‐Sil, 3M ESPE) applied to all specimens, left to react at 20°C for 2 min, followed by heat treatment at 38°C, 79°C, or 100°C for 1 min.
Study: 22035984
Drug: Heat treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat treatments (G38, G79, G100).
Study: 22035984
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (GC) received no silane treatment.
Study: 12032036
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of ropivacaine 1 mg/mL and fentanyl 2 microg/mL with epinephrine 2 microg/mL
Study: 12032036
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of ropivacaine 1 mg/mL and fentanyl 2 microg/mL without epinephrine
Study: 8834415
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg haloperidol
Study: 1650128
Drug: tetravalent rhesus
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: tetravalent rhesus rotavirus vaccine with small-volume (2.5-mL) antacid buffer
Study: 1650128
Drug: tetravalent rhesus
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: tetravalent rhesus rotavirus vaccine with large-volume (30-mL) antacid buffer
Study: 1650128
Drug: tetravalent rhesus
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: tetravalent rhesus rotavirus vaccine alone
Study: 1650128
Drug: tetravalent rhesus
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: tetravalent rhesus rotavirus vaccine with oral polio vaccine
Study: 1650128
Drug: oral polio
Normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral polio vaccine serotype 1
Study: 1650128
Drug: oral polio
Normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral polio vaccine serotype 2
Study: 1650128
Drug: oral polio
Normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral polio vaccine serotype 3
Study: 30859967
Drug: Valbenazine (open-label
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valbenazine (open-label treatment)
Study: 27823710
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (FCM) 1000 mg as a single infusion
Study: 27823710
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (FCM) 1000 mg
Study: 25024410
Drug: Intracoronary (IC)
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary (IC) salbutamol provocation at a dosage of 0.30 µg/min for 5 minutes
Study: 23062392
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 300 μg once daily
Study: 23062392
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (FF) 400 μg once daily
Study: 23062392
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 250 μg twice daily (active control)
Study: 15381545
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% tacrolimus ointment plus 308-nm excimer laser therapy (group A)
Study: 15381545
Drug: 308-nm excimer
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 308-nm excimer laser monotherapy (group B)
Study: 11194214
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg repaglinide at mealtimes (increased to 1 mg after 4 weeks)
Study: 9100602
Drug: hCRH (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCRH (1 microgram/kg) stimulation with 5% NaCl (0.06 mL.kg/min for 120 min)
Study: 9100602
Drug: Isotonic volume
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotonic volume loading (0.9% NaCl, 12 mL.kg.60 min)
Study: 944395
Drug: Flufenamic acid
Normalized name: Flufenamic acid
DrugBank: Flufenamic acid (DB02266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flufenamic acid (125 mg four to six times per attack)
Study: 944395
Drug: Common antimigraine
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common antimigraine drugs
Study: 20854770
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antidepressant medication and cognitive-behavioral therapy focused on suicide prevention (Comb)
Study: 20854770
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy focused on suicide prevention
Study: 3462459
Drug: Certain therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Certain therapies
Study: 29678987
Drug: Fibrinogen concentrate
Normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen concentrate (Octafibrin/Fibryga; Octapharma) - 4g administered within 24 hours of cardiopulmonary bypass
Study: 29678987
Drug: Cryoprecipitate -
Normalized name: Cryoprecipitate - CMV negative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryoprecipitate - 10 units (dose-equivalent to 4g) administered within 24 hours of cardiopulmonary bypass
Study: 26648582
Drug: Ascorbic acid-loaded
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid-loaded dissolving microneedle patch
Study: 25018648
Drug: Desvenlafaxine 200
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desvenlafaxine 200 mg/day
Study: 25018648
Drug: Desvenlafaxine 400
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desvenlafaxine 400 mg/day
Study: 12403958
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg trafermin
Study: 12403958
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg trafermin
Study: 12403958
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg trafermin (post hoc subgroup analysis)
Study: 7791258
Drug: Alprazolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.25 mg, administered four times a day from day 18 of the menstrual cycle through day 2 of the next cycle)
Study: 7791258
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized progesterone (300 mg, administered four times a day from day 18 of the menstrual cycle through day 2 of the next cycle)
Study: 7791258
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered four times a day from day 18 of the menstrual cycle through day 2 of the next cycle)
Study: 29779834
Drug: High-intensity intervention
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity intervention (weekly sessions for 12 months with home-based assessments and advice, n=100)
Study: 26303326
Drug: Standard 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 40 Hz stimulation therapy
Study: 21600592
Drug: 2-dose methylprednisolone
Normalized name: methylprednisolone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose methylprednisolone (30 mg/kg per dose, 8 hours preoperatively and operatively)
Study: 21600592
Drug: Single-dose methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose methylprednisolone (30 mg/kg per dose, operatively)
Study: 19249999
Drug: RES-C (Resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: RES-C (Resistance Training + Chiropractic Treatment)
Study: 16977477
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patch (3.5 mg/day during weeks 1 and 4; 7 mg/day during weeks 2 and 3)
Study: 15267123
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg/daily (1000 patients)
Study: 15267123
Drug: Clodronate 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 100 mg/weekly i.m. (800 patients)
Study: 15267123
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg/daily (100 patients)
Study: 15267123
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/daily (100 patients)
Study: 11300446
Drug: Cerivastatin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin (0.4 mg/d)
Study: 9258982
Drug: Oxybutynin 10
Normalized name: oxyBUTYnin 10% transdermal gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 10 mg controlled-release tablet ingested 2 hr after breakfast
Study: 9258982
Drug: Oxybutynin 10
Normalized name: oxyBUTYnin 10% transdermal gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 10 mg controlled-release tablet ingested during fasting
Study: 9258982
Drug: Oxybutynin 10
Normalized name: oxyBUTYnin 10% transdermal gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin 10 mg controlled-release tablet ingested 1 hr before breakfast
Study: 27492018
Drug: K2 tablet
Normalized name: vitamin K2 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: K2 tablet (12.4% w/w Kollidon(®) SR)
Study: 27492018
Drug: Immediate-release tablet
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release tablet (R)
Study: 11777120
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (PSCT and BMT/PSCT)
Study: 8410398
Drug: Treatment associated
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment associated with higher mortality
Study: 8410398
Drug: Treatment associated
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment associated with lower mortality
Study: 3104218
Drug: HB420 (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB420 (3.5 mg/tablet)
Study: 3104218
Drug: HB419 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HB419 (5 mg/tablet)
Study: 28317094
Drug: Dexamethasone 1
Normalized name: dexamethasone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1 mg.kg‐1
Study: 25566694
Drug: Transfusion threshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion threshold <7 g/dl
Study: 25566694
Drug: Transfusion threshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion threshold 10 g/dl
Study: 15177955
Drug: Intraoperative mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative mitomycin C (0.5 mg/ml for 5 minutes)
Study: 11224634
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin 5,000 units every 8 hours
Study: 11224634
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg once daily (plus two additional saline injections)
Study: 7899804
Drug: Arteflene (Ro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arteflene (Ro 42-1611) 300 mg or higher doses
Study: 7899804
Drug: Arteflene (Ro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arteflene (Ro 42-1611) 100, 300, 900, 1800, 2700, and 3600 mg
Study: 31209720
Drug: Sterilized probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterilized probiotic with 5.85 g polydextrose daily for 1 week (Group A)
Study: 31209720
Drug: Sterilized probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterilized probiotic without polydextrose daily for 1 week (Group B)
Study: 29526580
Drug: Home particle
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home particle repositioning maneuver (PRM) once weekly for five years
Study: 26607646
Drug: 80 kVp,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 kVp, 600 mAs, 35 ml CM at an injection rate of 3.5-4.5 ml/s
Study: 26607646
Drug: 100 kVp,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 kVp, 600 mAs, 70 ml CM at an injection rate of 4.5-5.5 ml/s
Study: 20361904
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium extended-release (ER) at a daily dosage initiated at 20 mg/kg for 21 days
Study: 10577853
Drug: Chemotherapy (mitomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (mitomycin 20 mg/m² IV on day 1, followed by tegafur 400 mg bid daily for 3 months)
Study: 29961161
Drug: Sirukumab 25
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab 25 mg every 4 weeks (q4w)